Observed Signal · Oct 29, 2026 · earnings · Source: SEC API · Impact: 4.6/5
10-Q Financial Filing Analysis for Lilly (2026-10-29)
Eli Lilly and Company reported strong financial results for the third quarter of 2026, driven by rapid uptake of its incretin portfolio. Total revenue reached $24.40 billion, up 39% year-over-year from $17.60 billion in Q3 2025, underpinned by massive volume expansion for Mounjaro ($10.72 billion, up 65%) and Zepbound ($5.35 billion, up 49%). Incretin medicines represented roughly two-thirds of total revenue for the first nine months of 2026. Consolidated net income for the quarter rose 16% to $6.45 billion ($7.22 diluted EPS), despite absorbing $4.18 billion in acquired in-process research and development (IPR&D) charges from external business development transactions including AtaiBeckley and Curevo. Operating cash flow expanded to $27.42 billion for the first nine months, allowing Lilly to fund aggressive manufacturing expansions ($8.44 billion in CapEx), strategic acquisitions ($10.69 billion net cash paid for acquisitions), and shareholder returns ($4.64 billion in dividends and $4.33 billion in share repurchases). While lower realized prices in the U.S. and China created pricing headwinds, Lilly's manufacturing efficiencies supported an 83.9% gross margin. Management continues to monitor pricing pressures from the Inflation Reduction Act, international reference pricing, and ongoing litigation regarding incretin compounding and patent enforcement.
Demonstrates the unprecedented commercial scaling of Lilly's tirzepatide franchise (Mounjaro and Zepbound) to an annualized run-rate exceeding $64 billion, confirming its dominant cardiometabolic market position alongside ongoing manufacturing and clinical investments.
Track Lilly Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Q3 2026 revenue increased 39% year-over-year to $24.40 billion, with Mounjaro generating $10.72 billion and Zepbound generating $5.35 billion.
- Quarterly net income reached $6.45 billion ($7.22 diluted EPS), absorbing $4.18 billion in acquired in-process R&D charges primarily from asset acquisitions of AtaiBeckley and Curevo.
- For the first nine months of 2026, operating cash flow stood at $27.42 billion, funding $8.44 billion in capital expenditures, $18.2 billion in business development activity, and $4.33 billion in share buybacks.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
10-Q Financial Filing Analysis for Johnson & Johnson (2026-10-21)
Johnson & Johnson reported fiscal Q3 2026 sales to customers of $25.40 billion, up 5.9% year-over-year (6.0% operational growth), driven by double-digit growth in Oncology and steady demand in MedTech, which offset biosimilar erosion from STELARA. However, consolidated net earnings collapsed to $210 million (diluted EPS of $0.09) from $5.15 billion in Q3 2025. This sharp profitability decline was primarily caused by a $5.5 billion pre-tax accrual recorded in Other (income) expense, net for a proposed comprehensive settlement of the talc ovarian cancer litigation, alongside a $1.0 billion in-process R&D charge from the Firefly Bio acquisition and ongoing Orthopaedics separation costs.
10-Q Financial Filing Analysis for CGI (2026-11-03)
Corcept Therapeutics reported significant financial growth for Q3 2026, driven by expanding commercial execution across its endocrinology franchise and the initial launch ramp of Lifyorli (relacorilant). Net product revenue rose 64.0% year-over-year to $340.5M, supported by $249.1M in hypercortisolism product sales and a $91.4M contribution from Lifyorli following its April 2026 U.S. launch. Operating income surged tenfold to $114.7M from $10.2M in Q3 2025, benefiting from gross margin expansion (cost of sales at just 1.4% of revenue) and disciplined operating expenditure leverage. Net income reached $126.8M, bolstered by a $6.5M net income tax benefit. Corcept maintains a robust balance sheet with $662.3M in cash and marketable securities and no long-term debt, positioning the company securely as it awaits the PDUFA target review date of December 17, 2026, for relacorilant in hypercortisolism.
West Pharma earnings prove it's not just a GLP-1 play
West Pharmaceutical Services reported strong Q3 2026 earnings, with adjusted EPS up 35.7% to $2.66 on sales of $874.5 million, beating analyst expectations. The company raised its full-year adjusted EPS guidance to $9.38-$9.48, citing robust demand for its premium drug-delivery components. While the GLP-1 boom, highlighted by Eli Lilly's 39% revenue growth, is a tailwind, West's growth is also driven by high-value component sales and margin expansion. Proprietary product sales grew 12.6%, with high-value components up 20.3% and now representing 53% of sales. Management expects operating margins to expand by nearly 300 basis points this year, supported by disciplined capital spending. The stock hit a 52-week high of $438.27, reflecting investor confidence in the company's diversified growth strategy.
Receive all future signals for Lilly & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.